Senseonics has received a PMA for the sensor out to 90 days, but plans call for a 180-day version of the device and eventually a version that lasts for a year.
Senseonics’ newly approved Eversense implantable continuous glucose monitoring (CGM) system could be in patient’s hands as early as next month. Tim Goodnow, the Germantown, MD-based company’s president and CEO spoke with MD+DI just a few hours removed from the start of the American Diabetes Association’s 78th Scientific Sessions in Orlando, FL. about the approval and upcoming plans for the device.
Read more: https://www.mddionline.com/eversense-latest-game-changer-diabetes-market